Cardiac toxicity in children and adolescents with Hodgkin lymphoma after chemoradiotherapy
Abstract
During the last decade in Russian clinics significant success in treatment of children with Hodgkin lymphoma has been reached. However, the using of doxorubicin in combination with mediastinal radiotherapy in cases of initial mediastinum involvement contributes to cardiomyopathy occurrence in different time from ending therapy. We have evaluated the cardiac status in 42 children with Hodgkin lymphoma after chemoradiotherapy. Evaluation of cardiac function was performed using standard M-mode echocardiography (with calculation ejection fraction- EF, left ventricular shortening fraction — FS) and electrocardiography with estimation of rate, rhythm and QTc duration. Reduced contractility was detected in 5 (11.9 %) children after chemoradiotherapy, that requires cardiac function monitoring and cardiologist’s consultation.
About the Authors
R. I. Feoktistov
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
O. A. Schurova
Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
J. G. Abugova
Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
J. Yu. Dyakonova
Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
O. V. Makarova
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
N. V. Myakova
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
N. B. Senyakovich
Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
E. V. Samochatova
Federal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical Hospital
Russian Federation
Russian Federation
Moscow
References
1. Treatment recommendations for children and adolescents with Hodgkin`s lymphoma in Russia based on the experiences of the DAL/GPOH-HD Trials suggested by Dieter Koerholz, Halle; Guenther Schellong, Muenster; Wolfgang Doerffel, Berlin with a Radiotherapy manual (Appendix) by Karin Dieckmann, Richard Poetter. Vienna, 2007.
2. Lanzkowsky P. Manual of pediatric hematology and oncology. Elsevier academic press, 2005.
3. Тимаков А. М. Поздние кардиотоксические эффекты химиолучевой терапии у детей с гемобластозами и другими злокачественными заболеваниями : Автореф. дис. … канд. мед. наук / А. М. Тимаков. – М.,1994.
4. Bricker J. T., Green D. M., D’Angio G. J. Cardiac toxicity after treatment for childhood cancer. NY: Wiley-Liss, Inc, 1994.
5. Тарасевич Р. А. Проблема антрациклиновой кардиотоксичности противоопухолевой терапии в детском возрасте / Р. А. Тарасевич, И. В. Бегун // Вопр. гематол., онкол., иммунопатол., педиатр. – 2005. – 4 (1): 58—64.
6. Hoppe R. T., Mauch P. T., Armitage J. O. et al. Hodgkin lymphoma. Philadelphia: Lippincott Williams & Wilkins, 2007.
7. Altman A. J. Supportive care of children with cancer. Baltimore: The Johns Hopkins University Press, 2004.
8. Elbl L., Hrstkova H., Tomaskova I. et al. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer 2006; 14 (2): 128—36.
9. Mladosievicova B., Fotinova A., Petrasova H. et al. Signal-averaged electrocardiography in survivors of Hodgkin’s disease treated with and without dexrazoxane. Neoplasma 2001; 48 (1): 61—5.
10. Tebbi C. K., London W. B., Friedman D. et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 2007; 25 (5): 493—500.
11. Aleman B. M., van den Belt-Dusebout A. W, De Bruin M. L. et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878—86.
12. Lipshultz S. E., Rifai N., Dalton V. M. et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145— 53.
13. Румянцев А. Г. Гематология/онкология детского возраста / А. Г. Румянцев, Е. В. Самочатова. – М.: Медпрактика-М, 2004.
14. Мурашко В. В. Электрокардиография / В. В. Мурашко, А. В. Струтынский. – М.: Медпресс, 2000.
15. Бегун И. В. Инструментальные показатели сердечной функции и уровень сывороточного тропонина I у детей с острым промиелоцитарным лейкозом на этапах полихимиотерапии / И. В. Бегун [и др.] // Мед. журн. – 2005. – 4: 18—20.
16. Schellong G. The balance between cure and late effects in childhood Hodgkin’s lymphoma: the experience of the German — Austrian Study-Group since 1978. Ann Oncol 1996; 7 (4): 67—72.
Review
For citations:
Feoktistov R.I., Schurova O.A., Abugova J.G., Dyakonova J.Yu., Makarova O.V., Myakova N.V., Senyakovich N.B., Samochatova E.V. Cardiac toxicity in children and adolescents with Hodgkin lymphoma after chemoradiotherapy. Oncohematology. 2010;(1):31-36. (In Russ.)
Views:
8974
Email this article 